20180913 IN Pipeline with Venture Captial Focus

I am happy to see a biotech San Diego based company raise $4 million!  On a more positive note, our Senior Executive Advisors are all around the country and world with wide access to capital. #seaprogram #jdmorris

DISCLAIMER: This information is provided by AP, Bloomberg, Forbes, Fortune, preqin, Reuters, TechCrunch, VentureBeat, Wall Street Journal (WSJ), and other 3rd party sources. Please check with the company website as this a  beta blog.

IN PIPELINE 09-13-2018 VENTURE CAPITAL

• Prominex, Inc., a San Diego, CA-based molecular diagnostic company focused on point-of-care infectious disease testing, completed its $4m Series A-1 financing
• Avvay, a Franklin, Tenn.-based platform for content creators to find and book locations for their projects and events, raised $1m in seed funding
• Prokaryotics, Inc., a Union, N.J.-based biopharmaceutical company engaged in the discovery and development of novel anti-infective drugs, has been awarded its second Small Business Innovation Research Grant (SBIR) valued at up to $2.3m
• Bloom Credit, a NYC-based financial wellness platform for consumers and lenders to build a sound credit relationship, raised $3.87m in seed funding
• Domicile, a Seattle, WA-based developer of technology-driven business accommodation platform, raised $5m in seed funding
• Hiretual, a Mountain View, CA-based AI-driven HR technology company, raised $5M in Series A funding
• Growers Holdings, Inc., a Seattle, Washington and Raleigh, N.C.-based agtech startup, raised $5M in Series A financing
• RenalGuard Solutions, a Milford, MA-based medical device company focused on innovative technologies for the cardiac and vascular markets, completion of a $7m financing
• Seed CX, a Chicago, IL-based licensed cryptocurrency exchange that offers institutional trading and settlement for both spot market and CFTC-regulated derivatives, raised $15m in Series B funding
• HYP3R, a San Francisco, CA-based location-based marketing company, raised $17m in Series A financing
• Datrium, a Sunnyvale, CA-based provider of a server flash storage system, raised $60m in Series D funding
• Shift Technologies, a San Francisco-based platform to buy and sell used cars, raised more than $140 million in Series D equity and debt financing
• Irrimax, an Atlanta, GA-based medical device company, received an investment from Decathlon Capital Partners
• Basic Fun!, a Boca Raton, Florida-based toy and novelties company, received an equity investment from Falcon Investment Advisors, a Boston-based investment fund
• Technori, a Chicago, IL-based active startup platform, received a seven-figure investment from DV Partners, led by SMS Assist Founder and Chairman Mike Rothman
• OneOncology, a Nashville, Tenn.-based partnership of independent community oncology practices and finance and technology experts, received an investment from General Atlantic
• GTY Technology Holdings is to buy CityBase, Inc., a Chicago, IL-based provider of a tech platform for people and businesses to interact with utilities and government agencies, for $160m in cash and stock

PRESS RELEASE POMINEX INC

SAN DIEGO–(BUSINESS WIRE)–Prominex, Inc., a molecular diagnostic company focused on point-of-care infectious disease testing, today announces the completion of its Series A-1 financing, raising $4 million from Casdin Capital LLC and its founding CEO. The Series A-1 financing will provide funding to advance the development of its infectious disease assays and commence an instrument development partnership with Invetech, a global leader in point-of-care instrument design and development.

Prominex’s Founder and CEO Paul Thomas commented, “Our Validex System delivers a 5-minute sample-to-answer molecular test result that will enable a broad spectrum of point-of-care testing from simple screening to more complex syndromic panel assays. We believe our Validex System holds significant promise to improve patient care and outcomes in time-critical clinical situations and to realize significant cost savings by optimized patient management and triage of patients to the most appropriate care setting.”

About Prominex

Prominex was founded in 2016 with a primary focus on the development of molecular diagnostic assays for point-of-care infectious disease testing. The novel molecular amplification and waveguide detection technologies incorporated into our Validex System enables the development of ultrafast, accurate, easy-to-use, highly multiplexed, and low-cost molecular diagnostic assays. For more information, visit www.Prominex.com.